Literature DB >> 21068441

TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis.

Glenda Trujillo1, Alessia Meneghin, Kevin R Flaherty, Lynette M Sholl, Jeffrey L Myers, Ella A Kazerooni, Barry H Gross, Sameer R Oak, Ana Lucia Coelho, Holly Evanoff, Elizabeth Day, Galen B Toews, Amrita D Joshi, Matthew A Schaller, Beatrice Waters, Gabor Jarai, John Westwick, Steven L Kunkel, Fernando J Martinez, Cory M Hogaboam.   

Abstract

Idiopathic pulmonary fibrosis is characterized by diffuse alveolar damage and severe fibrosis, resulting in a steady worsening of lung function and gas exchange. Because idiopathic pulmonary fibrosis is a generally progressive disorder with highly heterogeneous disease progression, we classified affected patients as either rapid or slow progressors over the first year of follow-up and then identified differences between the two groups to investigate the mechanism governing rapid progression. Previous work from our laboratory has demonstrated that Toll-like receptor 9 (TLR9), a pathogen recognition receptor that recognizes unmethylated CpG motifs in bacterial and viral DNA, promotes myofibroblast differentiation in lung fibroblasts cultured from biopsies of patients with idiopathic pulmonary fibrosis. Therefore, we hypothesized that TLR9 functions as both a sensor of pathogenic molecules and a profibrotic signal in rapidly progressive idiopathic pulmonary fibrosis. Indeed, TLR9 was present at higher concentrations in surgical lung biopsies from rapidly progressive patients than in tissue from slowly progressing patients. Moreover, fibroblasts from rapid progressors were more responsive to the TLR9 agonist, CpG DNA, than were fibroblasts from slowly progressing patients. Using a humanized severe combined immunodeficient mouse, we then demonstrated increased fibrosis in murine lungs receiving human lung fibroblasts from rapid progressors compared with mice receiving fibroblasts from slowly progressing patients. This fibrosis was exacerbated by intranasal CpG challenges. Furthermore, CpG induced the differentiation of blood monocytes into fibrocytes and the epithelial-to-mesenchymal transition of A549 lung epithelial cells. These data suggest that TLR9 may drive the pathogenesis of rapidly progressive idiopathic pulmonary fibrosis and may serve as a potential indicator for this subset of the disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21068441      PMCID: PMC3235647          DOI: 10.1126/scitranslmed.3001510

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  59 in total

1.  Peripheral blood fibrocytes: differentiation pathway and migration to wound sites.

Authors:  R Abe; S C Donnelly; T Peng; R Bucala; C N Metz
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

2.  Thin-section CT findings in rheumatoid arthritis-associated lung disease: CT patterns and their courses.

Authors:  M Akira; M Sakatani; H Hara
Journal:  J Comput Assist Tomogr       Date:  1999 Nov-Dec       Impact factor: 1.826

3.  Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis.

Authors:  K Tsukamoto; H Hayakawa; A Sato; K Chida; H Nakamura; K Miura
Journal:  Thorax       Date:  2000-11       Impact factor: 9.139

4.  Evidence that fibroblasts derive from epithelium during tissue fibrosis.

Authors:  Masayuki Iwano; David Plieth; Theodore M Danoff; Chengsen Xue; Hirokazu Okada; Eric G Neilson
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 5.  Cellular and molecular mechanisms of fibrosis.

Authors:  T A Wynn
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

6.  Raised plasma concentrations of alpha-defensins in patients with idiopathic pulmonary fibrosis.

Authors:  H Mukae; H Iiboshi; M Nakazato; T Hiratsuka; M Tokojima; K Abe; J Ashitani; J Kadota; S Matsukura; S Kohno
Journal:  Thorax       Date:  2002-07       Impact factor: 9.139

7.  TLR9 contributes to antiviral immunity during gammaherpesvirus infection.

Authors:  Simone Guggemoos; Doris Hangel; Svetlana Hamm; Antje Heit; Stefan Bauer; Heiko Adler
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

8.  Peripheral blood fibrocytes from burn patients: identification and quantification of fibrocytes in adherent cells cultured from peripheral blood mononuclear cells.

Authors:  Liju Yang; Paul G Scott; Jennifer Giuffre; Heather A Shankowsky; Aziz Ghahary; Edward E Tredget
Journal:  Lab Invest       Date:  2002-09       Impact factor: 5.662

9.  Responsiveness of fibrocytes to toll-like receptor danger signals.

Authors:  Carole Balmelli; Marco P Alves; Esther Steiner; Daniel Zingg; Nadja Peduto; Nicolas Ruggli; Heidi Gerber; Kenneth McCullough; Artur Summerfield
Journal:  Immunobiology       Date:  2007-11-13       Impact factor: 3.144

10.  Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease.

Authors:  Karolina A Rygiel; Helen Robertson; Helen L Marshall; Marcin Pekalski; Liena Zhao; Trevor A Booth; David E J Jones; Alastair D Burt; John A Kirby
Journal:  Lab Invest       Date:  2007-12-03       Impact factor: 5.662

View more
  62 in total

1.  Heterogeneity of Fibroblasts and Myofibroblasts in Pulmonary Fibrosis.

Authors:  David M Habiel; Cory M Hogaboam
Journal:  Curr Pathobiol Rep       Date:  2017-05-02

2.  Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis.

Authors:  Yong Huang; Shwu-Fan Ma; Milena S Espindola; Rekha Vij; Justin M Oldham; Gary B Huffnagle; John R Erb-Downward; Kevin R Flaherty; Beth B Moore; Eric S White; Tong Zhou; Jianrong Li; Yves A Lussier; MeiLan K Han; Naftali Kaminski; Joe G N Garcia; Cory M Hogaboam; Fernando J Martinez; Imre Noth
Journal:  Am J Respir Crit Care Med       Date:  2017-07-15       Impact factor: 21.405

3.  Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study.

Authors:  MeiLan K Han; Yueren Zhou; Susan Murray; Nabihah Tayob; Imre Noth; Vibha N Lama; Bethany B Moore; Eric S White; Kevin R Flaherty; Gary B Huffnagle; Fernando J Martinez
Journal:  Lancet Respir Med       Date:  2014-04-21       Impact factor: 30.700

Review 4.  Toll like receptors in diseases of the lung.

Authors:  Melissa A Kovach; Theodore J Standiford
Journal:  Int Immunopharmacol       Date:  2011-05-30       Impact factor: 4.932

5.  Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis.

Authors:  Fei Liu; David Lagares; Kyoung Moo Choi; Lauren Stopfer; Aleksandar Marinković; Vladimir Vrbanac; Clemens K Probst; Samantha E Hiemer; Thomas H Sisson; Jeffrey C Horowitz; Ivan O Rosas; Laura E Fredenburgh; Carol Feghali-Bostwick; Xaralabos Varelas; Andrew M Tager; Daniel J Tschumperlin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-12-12       Impact factor: 5.464

6.  Host-Microbial Interactions: Idiopathic Pulmonary Fibrosis in Technicolor.

Authors:  David N O'Dwyer; David Habiel; Cory Hogaboam
Journal:  Am J Respir Crit Care Med       Date:  2017-06-15       Impact factor: 21.405

7.  Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.

Authors:  Lynne A Murray; Huilan Zhang; Sameer R Oak; Ana Lucia Coelho; Athula Herath; Kevin R Flaherty; Joyce Lee; Matt Bell; Darryl A Knight; Fernando J Martinez; Matthew A Sleeman; Erica L Herzog; Cory M Hogaboam
Journal:  Am J Respir Cell Mol Biol       Date:  2014-05       Impact factor: 6.914

Review 8.  Regulation of wound healing and organ fibrosis by toll-like receptors.

Authors:  Peter Huebener; Robert F Schwabe
Journal:  Biochim Biophys Acta       Date:  2012-12-04

Review 9.  Animal models of fibrotic lung disease.

Authors:  Bethany B Moore; William E Lawson; Tim D Oury; Thomas H Sisson; Krishnan Raghavendran; Cory M Hogaboam
Journal:  Am J Respir Cell Mol Biol       Date:  2013-08       Impact factor: 6.914

10.  Modeling Idiopathic Pulmonary Fibrosis in Humanized Severe Combined Immunodeficient Mice.

Authors:  David M Habiel; Milena S Espindola; Ana L Coelho; Cory M Hogaboam
Journal:  Am J Pathol       Date:  2018-02-17       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.